List view / Grid view
Christian Andersson, Product Development Manager at Takara Bio discusses hiPS-derived beta cells, which offer an unprecedented opportunity for diabetes research to model human physiology and ‘diseases in a dish’. Christian looks into the potential for new discoveries for diabetes and other metabolic diseases...
Flow cytometry is a laser-based technology – a powerful tool for drug discovery and the screening process and can be used in all settings, including research, clinical, pharmaceutical and biotechnology. The increasing capabilities of flow cytometers make their incorporation into drug development and screening optimal...
Adenosine triphosphate (ATP)-gated ion channels serve important neurophysiological functions and have been an attractive class of drug target for a decade...
Understanding how a cell responds to different stimuli producing diverse protein profiles can provide information about cell signalling pathways, generating more specific treatments...
Ilpo Kulmala, Principal Scientist at VTT Ltd, explains the role that transportation plays in the spread of infectious diseases...
Despite that over 1,900 mutations of the cystic fibrosis transmembrane conductance regulator cause cystic fibrosis, only two treatment options exist.
In this Screening In-Depth Focus, scientists from the Assay Development and Screening Platform of Helmholtz Zentrum München provide an overview of different high-throughput screening (HTS)-applicable assay types that can be applied to drug discovery campaigns. Plus an interview with Lee Babiss, CEO of drug discovery firm X-Rx, on the benefits…
In this Personalised Medicines In-Depth Focus, Dr Adrian Harel talks about the importance of developing a diagnostic test and better treatments for traumatic brain injury. Plus, Caroline Richards, Editor of Drug Target Review explores the need for mutation specific treatments in cystic fibrosis...
NGS technologies have been employed in a wide range of areas in drug discovery, including drug target identification, biomarker discovery and biopharmaceutics development. Pushpanathan Muthuirulan of the National Institutes of Health gives us an overview of this in his article in our NGS In-Depth Focus. Meanwhile, the possibilities that RNA-Seq…
11 December 2016 | By Drug Target Review
Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs...
The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
The covalent modification of proteins by the attachment of ubiquitin (ubiquitination) is best known for its function to label proteins for proteasomal degradation. However, ubiquitination also plays non-proteasomal roles during signal transduction, DNA repair and protein sorting...
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
